Retatrutide

a.k.a. LY3437943 · Triple Agonist

Next-gen triple agonist (GLP-1/GIP/Glucagon) for metabolic research

💉 Subcutaneous Injection

Purity

≥98%

Form

Lyophilized Powder

Storage

-20°C

Research Applications

Fat LossAnti-Aging

Select Size

Quantity

Total

$120.00

Research Use Only · Not for human consumption. Intended for in vitro laboratory and research applications.

Description

Retatrutide is a novel triple agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. It represents the next generation of metabolic peptides, showing superior efficacy in clinical trials for weight management research.

Mechanism of Action

Retatrutide uniquely activates three hormone receptors: GLP-1 for appetite suppression, GIP for insulin sensitivity, and glucagon for increased energy expenditure. This triple mechanism creates synergistic metabolic effects.

Specifications

Purity: ≥98%
Form: Lyophilized Powder
Storage: -20°C

Related Peptides

View All

Weight Management

Semaglutide

The original GLP-1 agonist for metabolic research

From $30

Weight Management

Tirzepatide

Dual GIP/GLP-1 agonist for advanced metabolic research

From $60

Weight Management

AOD-9604

HGH fragment for fat metabolism without growth effects

From $30

$120.00

10mg (Single Vial) × 1